InflaRx N.V. (IFRX) Fundamentals

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
SHARE INFORMATION
Market Cap$ 98,132,354
Shares Outstanding44,203,763
Float39,812,177
Percent Float90.07%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -1.25
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions54
Institutional Holdings Date2022-08-31
Institutional Bought Previous 3 Months107,430
Institutional Holdings Percent13.0%
Institutional Sold Previous 3 Months469,991
Insider Holdings Date-
Insider Bought Previous 3 Months-
Insider Holdings Percent0.0
Insider Sold Previous 3 Months-
Insider Shares Owned-
TRADING INFO
52 Week High$ 5.69
52 Week Low$ 0.78
52 Week High Change$ -19.27
21 Day Moving Average$ 2.4329
21 Day Extended Moving Average$ 2.4764
50 Day Moving Average$ 2.3442
50 Day Extended Moving Average$ 2.3209
200 Day Moving Average$ 2.4915
200 Day Extended Moving Average$ 2.4242
10 Day Average Volume167,794
20 Day Average Volume130,717
30 Day Average Volume162,480
50 Day Average Volume429,097
Alpha0.000942
Beta1.3357
Standard Deviation0.274950
R20.063027
7 Day Price Change$ -0.46
7 Day Percent Change-17.16%
21 Day Price Change$ 0.01
21 Day Percent Change0.45%
30 Day Price Change$ -0.28
30 Day Percent Change-11.2%
Month to Date Price Change$ 0.01
Month to Date Percent Change0.45%
Quarter to Date Price Change$ 0.77
Quarter to Date Percent Change53.1%
180 Day Price Change$ -0.03
180 Day Percent Change-1.33%
200 Day Price Change$ 0.11
200 Day Percent Change5.21%
Year to Date Price Change$ -2.54
Year to Date Percent Change-53.36%

InflaRx N.V. (IFRX) Key Ratios

PROFITABILITY
EBIT Margin0.0%
EBITDA Margin0.0%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book1.00
Total Debt To Equity0.00
Int Coverage-755.60
Current Ratio9.90
Leverage Ratio1.20
Quick Ratio9.00
Long Term Debt To Capital0.01
VALUATION MEASURES
PE Ratio-2.40
Enterprise Value$ 3,326,246
Price to Sales0.00
Price to Free Cash-2.00
PE High Last 5 Years-4.10
Price To Book1.00
Price To Cash Flow0.00
PE Low Last 5 Years-36.00
Price to Tangible Book1.00
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-28.61
Return on Equity-31.62
Return on Capital-33.53

InflaRx N.V. (IFRX) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorErnst & Young Wirtschaftsprüfungsgesellschaft mbH
CEONiels Riedemann
Emplyoees59
Last AuditUQ
CIK0001708688
IndustryBiotechnology
SectorHealthcare
NAICS-
CONTACT INFO
AddressWinzerlaer Strasse 2
Jena, 7745
Websitehttps://www.inflarx.de
Facsimile-
Telephone+49 3641508180
Emailhherklots@lifesciadvisors.com


Your Recent History
NASDAQ
IFRX
InflaRx NV
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.